Memantine shows therapeutic potential in ADHD
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
The study randomized 40 patients aged 18–45 years with ADHD to receive memantine (n=20; mean age 34.7 years) or placebo (mean age 31.5 years) for 6 weeks. Treatment was administered at 10 mg/day in the first week and then 20 mg/day thereafter. All patients completed the Conners' screening questionnaire.
Results showed significant differences in behaviour and attention deficit between the two groups after 6 weeks of treatment (p<0.001). Compared with placebo, memantine produced improvements from baseline in the following symptoms: inattention/memory problems, hyperactivity/restlessness and impulsivity/emotional lability.
Moreover, the ADHD Index significantly decreased over the treatment course in the memantine group (from 56.4 at baseline to 43.9 at week 3 and 36.7 at week 6) but remained stable in the placebo group (from 59.3 at baseline to 57.2 at week 3 and 59.7 at week 6).
In terms of safety, memantine was tolerable, and side effects were mild in severity. Commonly reported adverse events included dizziness, confusion, constipation, back pain and sleepiness.
The findings suggest that memantine is safe and effective for treating ADHD, researchers said. However, further studies are needed to evaluate such effects.